Other mechanisms of drug resistance include bypass mechanisms, such as MET overexpression, alterations in other HER family proteins, downstream activations of the RAS or PI3K pathways, and transformation from NSCLC to small cell lung cancer (SCLC; Gibbons & Byers, 2014). This evidence concerns the gene MET and small cell lung carcinoma.